Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having…
Retinal Vein Occlusion
Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Like other retinal disease therapy markets, the retinal vein occlusion (RVO) with macular edema (ME) market in the United States is unique in that it is dominated by Genentech’s Avastin, an…